Darolutamide
Anti-Androgens
Sold as Nubeqa
- Drug class
- Anti-Androgens
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 7
Overview
Darolutamide is an active pharmaceutical ingredient in the Anti-Androgens group (L02BB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 5 | May 1, 2026 |
| EU European Union | EMA | 1 | August 29, 2025 |
| CA Canada | Health Canada | 1 | September 15, 2025 |
GBUnited Kingdom· MHRA
5 products
Uses
1). 1). 1).
How to take
EUEuropean Union· EMA
1 product
Uses
1). 1). 1).
How to take
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Darolutamide. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000100677 · revised May 1, 2026
- [2]European Medicines Agency · EMEA/H/C/004790 · revised August 29, 2025
- [3]Health Canada (DPD) · 02496348 · revised September 15, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.